A Closer Look: Hutchison MediTech TCM Deal With Nestle Reaches Into Pharma Development
This article was originally published in PharmAsia News
Executive Summary
A new joint venture between Nestle Health Science and Chi-Med covering nutritional and medicinal products derived from botanical plants also includes Phase III drug HMPL-004, ending the Chinese R&D firm’s long search for a partner.
You may also be interested in...
Nestlé Health Science Plans Continuum Of Care
Nestlé’s announcement on May 24 that its new health sciences subsidiary is buying Prometheus Laboratories, a gastrointestinal drug and diagnostic company, takes the food company in a new direction, but also raises questions for pharma.
Nestle Gains GI Diagnostics For Nutritional Health Biz Via Prometheus Deal
Nestle Health Science will add gastrointestinal diagnostic services to its nutritional health business by acquiring Prometheus Laboratories for undisclosed terms in a deal announced May 24.
Chi-Med Expected To Double Revenue By 2015, Backed By Urbanization, Healthcare Reform And TCM Performance in China
SHANGHAI - UK-listed Chinese healthcare company Chi-Med is expected to double its current revenues of $111 million in the next five years, backed by rapid growth in traditional Chinese medicine and consumer products, U.S. investment banking firm Piper Jaffray said in an Aug. 4 research note